Software supported modelling in pharmacokinetics. by Telgmann, Regina et al.
Software Supported Modelling in
Pharmacokinetics
Regina Telgmann1, Max von Kleist2 and Wilhelm Huisinga2
1 CiT GmbH,
Oldenburger Str. 200,
D-26180 Rastede, Germany
r.telgmann@cit-wulkow.de
2 Freie Universita¨t Berlin,
Department of Mathematics and Informatics,
Arnimallee 6,
D-14195 Berlin, Germany
{kleist,huisinga}@mi.fu-berlin.de
Abstract. A powerful new software concept to physiologically based
pharmacokinetic (PBPK) modelling of drug disposition is presented. It
links the inherent modular understanding in pharmacology with orthog-
onal design principles from software engineering. This concept allows for
flexible and user-friendly design of pharmacokinetic whole body models,
data analysis, hypotheses testing or extrapolation. The typical structure
of physiologically-based pharmacokinetic models is introduced. The re-
sulting requirements from a modelling and software engineering point of
view and its realizations in the software tool MEDICI-PK are described.
Finally, an example in the context of drug-drug interaction studies is
given, that demonstrates the advantage of defining a whole-body phar-
macokinetic model in terms of the underlying physiological processes
quite impressively: A system of 162 ODEs is automatically compiled
based on the specification of 7 local physiological processes only.
1 Introduction
Pharmacokinetics is the study of the time course of drug and metabolite levels in
different fluids, tissues, and excreta of the body [12]. This includes the investiga-
tion and understanding of the processes of absorption, distribution, metabolism,
and excretion (ADME). The pharmacokinetic profile of a drug strongly influences
its delivery to biological targets, thereby affecting its efficacy and potential side
effects. Following studies in the late 1990s indicating that poor pharmacokinetics
and toxicity were important causes of costly late-stage failures in drug develop-
ment, it has been widely perceived that these areas need to be considered as early
as possible in the drug discovery process [1]. Today’s combinatorial chemistry
and high throughput screening methods anlarged the space of drug candidates
significantly, creating actual needs for in silico pharmacokinetic analysis to sup-
port the drug development pipeline. The pharmacokinetics of a compound are
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typically understood, analyzed and interpreted in the context of their underlying
ADME processes. However, there is no unique mathematical model for any of
these processes; usually a number of different models with different underlying
assumptions, parameterization and applicability are concurrent.
To efficiently support in silico modelling and simulation in pharmacokinet-
ics, we propose to inherit the inherent modular structure, which is based on the
physiological processes, to the software tool. We describe the concepts of modu-
larity and orthogonality as fundamental principles for the design of a virtual lab
in pharmacokinetics. The above mentioned design principles have recently been
realized successfully in the software tool MEDICI-PK, that is especially designed
to fit the needs in pharmacokinetic modelling. Our approach is illustrated by an
example from drug-drug interaction studies.
2 Mathematical Modelling in Physiologically Based
Pharmacokinetics (PBPK)
Fig. 1. Organ structure of a physiologically based pharmacokinetic model.
A physiologically based pharmacokinetic (PBPK) whole body model is a
special type of compartmental model, in which the compartments represent
anatomical volumes, such as organs or tissues. The compartments are connected
in an anatomically meaningful way, to simulate drug exchange via the blood
flow. The conceptional representation of a 15 organ PBPK model is shown in
Fig. 1. Each compartment is further subdivided into the four phases erythro-
cytes, plasma, interstitium and cellular space (see Fig. 1). Many physiological
processes in pharmacokinetics are accessible for a mechanistic description at this
resolution. Typically, following processes are modelled:
– Convection of drug molecules by the blood flow
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– Binding to macromolecules in plasma and interstitial space
– Distribution into tissue
– Diffusion or active transport across the cellular membrane
– Metabolism or interaction with metabolic networks or signalling pathways
etc.
There are many levels of mathematical description for a certain biological process
(e.g., each of the physiological processes stated in the above list). To give an ex-
ample, the process of protein binding (complex formation) between a compound
and some macromolecule can be explicitly modelled in terms of the correspond-
ing differential equations derived from the law of mass action. However, often
it is assumed that the binding process is fast in comparison to other processes
and therefore in dynamical equilibrium (quasi-stationarity). This results in some
algebraic equation, often still accounting for saturation effects of the binding pro-
cess. A further simplification finally results in a linear algebraic equation that
is not capable of accounting for saturation effects, however it may be directly
parameterized in terms of a frequently generated in vitro parameter.
Each mathematical model has its range of applicability and typically requires
different knowledge about the process and in particular different input param-
eters. In broad terms, a chosen model will be a compromise between detailed
mechanistic description and required ”quality” of the input parameters. Typ-
ically, the knowledge and the quality of parameters increases along the drug
discovery and development process so that adaptation of the model to the cur-
rent knowledge and parameter quality is possible (and should be aimed for).
The characterization of the PBPK model already suggests a modular de-
scription of the whole body model, especially in drug discovery. In mathemat-
ical terms, a PBPK model constitutes a set of differential/algebraic equations
describing the underlying processes. The current status of software development
in pharmacokinetics is dominated by either a purely equation based approach—
contradicting user-friendliness—or implementing a static model—contradicting
flexibility [10]. Instead, the requirements on user-friendliness and flexibility can
be fulfilled by the use of sophisticated modular software concepts and structures,
as outlined in the next section.
3 Modular Software Design
To support the specification of a whole-body pharmacokinetic model, a variety
of physiological processes (mentioned above) and a collection of different math-
ematical models to describe these processes have to be regarded. In practice,
identical processes in different compartments will often be described by identi-
cal mathematical models; –however, from a software engineering point of view it
is important to encapsulate the mathematical descriptions into modular parts.
These modular parts (”models”), collected in a model library, are defined only
once and can be re-used inside the whole PK model wherever suitable. This
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prevents re-definition and rewriting and supports the even treatment of same
processes wherever wanted.
The models are specified in terms of concentrations and parameters, but (a
prerequisite for this approach) are independent of a specific numerical value of
the parameters. Using the ”same” model in a different context requires evaluat-
ing different parameter values for the same mathematical expressions, depending
on the context where the model is used. A given topology (like the 15 organs
example) linked together with a selection of models from the library for each
compartment therefore builds a description of the PBPK model which is still
independent of any specific numerical values. It may be evaluated for any selec-
tion of parameter values. The parameters to which a models (might) refer can be
classified as compound dependent, species/individual dependent, dependent on
both or on none. This classification suggests the introduction of corresponding
software objects building another orthogonal structure. For the full specification
of a PBPK model, parameters and compound- as well as species-specific values
of these parameters have finally to be linked—this is realized by the simulation
object.
Parameter definition
Compounds (c):
- definitions
- parameters (o)
Mix parameters (c+i)
Individuals (i):
- definitions
- parameters (o)
Simulation scenario
Simulation object
- full body model
- individual
- compounds
- dosing strategies
Simulation results
Model definition
Organs (o) + Phases
Topology 
templates
Physiological process 
library
type (binding, diffusion, 
metabolisms, etc.)
-description, formulas
- general parameter 
dependencies (o,c,i)
Full body model:
- topology
- selected 
processes
Fig. 2. Schematic illustration of the orthogonal approach to software supported phar-
macokinetic modelling.
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Because the models address the concentration of a compound by fixed terms
(e.g. ”Comp1”) it is necessary to map the actual selection of a compound to this
expression. Models which consider only one compound need no mapping since
this is internally handled. Multi-compound models that consider more than one
compound (e.g, needed in metabolism models for interactions between different
compounds) necessitate an explicit mapping of the terms addressing the different
compound concentrations. For instance, the simple metabolism model
V
dC(1)
dt
= k1C
(1)
− k2C
(1)C(2)
V
dC(2)
dt
= −k1C
(2) + k2C
(1)C(2)
will be evaluated for two compounds A and B, only if the mapping between
compounds (A,B) and concentration terms (C(1), C(2)) in the above equations
is performed, e.g., A to C(1) and B to C(2) . As soon as all missing mappings
are defined, the PBPK model is completed.
When starting the simulation, the resulting differential equation system is au-
tomatically generated, including the assignment of all compound-specific param-
eter values and species-specific physiological parameter values to the respective
processes. An illustrative example from drug-drug interaction studies is given in
the next section that illuminates the advantage of defining a whole-body PBPK
model in terms of the underlying (local) physiologically processes quite impres-
sively.
4 Examples
Some drugs are administered as so-called pro-drugs that are metabolized into
active compounds by liver enzymes. One example is Oseltamivir, better known
as Tamiflu [8]. Tamiflu is the main antiflu medicine recommended by the World
Health Organization (WHO) [2]. In anticipation of a flu pandemic, the WHO
suggests that countries should stockpile enough Tamiflu to allow the treatment
of at least a quarter of their population. At present time, however, the supplies
of Tamiflu are enough to cover about 2% of the world population only. Recently,
Hill et al. [7] highlighted a way to effectively double the supplies of Tamiflu:
When administered with a second drug, called probenicid, Tamiflu excretion into
the urine is stopped. As a result, only half of the normal doses of Tamiflu are
needed. This ”wartime tactic” could be used to double power of scarce resources
of Tamiflu in case of a flu pandemic [2].
Here, in silico modelling and simulation could help to better understand and
possibly further optimize the co-administration effects. Motivated by the above
example, we want to illustrate how the previously introduced software concepts,
–realized in MEDICI-PK, can be used to efficiently model the phenomena of
pro-drug administration and drug-drug interaction. Our aim is not to reproduce
clinical data, but rather to demonstrate the power of our orthogonal and mod-
ular approach to pharmacokinetic modelling.
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Table 1. Brief overview over the performed simulations.
description interactions dosing
independent pharmacokinetics - A: 2[mg/kg body weight] i.v.
B: 2[mg/kg body weight] i.v.
C: 2[mg/kg body weight] i.v.
conversion of pro-drug A to A → B A: 2[mg/kg body weight] i.v.
active metabolite B C: 2[mg/kg body weight] i.v.
conversion of pro-drug A to B A → B↓` C A: 2[mg/kg body weight] i.v.
competition for active tubular C: 2[mg/kg body weight] i.v.
excretion between B and C
The starting point is the definition of the building blocks in our PBPK model.
This is done in terms of the relevant physiological processes like: (a) i.v. ab-
sorption, (b) linear protein binding, (c) passive diffusion, (d) tissue distribution
(according to [6]), (e) saturable metabolism, (f) renal excretion. Each of the pro-
cesses (modules) is defined in a ’model basis’ by a corresponding mathematical
equation. For instance, the processes of saturable metabolism is defined by
vmeta =
V metamax Cu
Kmetam + Cu
, (1)
with maximum reaction velocity V metamax and Michaelis-Menten constant K
meta
m .
The concentration of unbound drug is denoted by Cu . The process of excretion
is specified by
vexcr = QGFCu +
V renmaxCu
Krenm + Cu
−Qre−abs.Cu . (2)
The parameter V renmax denotes the maximum velocity of the saturable active tubu-
lar excretion process with Michaelis-Menten constant Krenm . QGF and Qre−abs.
are the glomerular filtration rate and the passive reabsorption rate respectively.
The renal excretion has been modelled as a function of three processes: (i) pas-
sive glomerular filtration (efflux), (ii) active tubular secretion (efflux) and (iii)
passive reabsorption. Metabolic clearance in the kidney has been neglected. In
total, seven local processes have been defined to model the whole body pharma-
cokinetics of the three compounds.
The overall PBPK model is then defined by the full body template that
links the local physiological process modules on the organ level. For efficiancy,
it is possibe to define a generic organ structure, which is taken as a default
for the initialization of the entire list of organ models. Subsequent individual
modifications are possible in order to model organ specific processes, like e.g.,
excretion by the kidneys. Next, we specify the physiological parameters of the
considered species, in our case a 250 g weighting male rat. These values are later
needed to fill the model parameters. Finally, we specify the compound-specific
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data. Motivated by the Tamiflu example, we consider three compounds named
A, B, and C; a pro-drug, an active metabolite and a competitive inhibitor for
the secretion (of compound B).
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Fig. 3. Simulation results as concentration vs. time profiles in venous plasma for (I.)
independent pharmacokinetics (top left) and (II.) conversion of pro-drug A to B (top
right). The simulation results for (III.) competition for tubular excretion of compounds
B and C are shown in the middle and bottom panels. The middle left and right panels
shows the concentration vs. time profiles in the venous plasma and interstitial space
of the lung, while the bottom panels show the profiles in the cellular space of the liver
(bottom left) and kidney.
At this stage, the three constituents are completely independent. The PBPK
model is specified in terms of parameters, however, no actual numerical values
are assigned in the model. Only if we map the specific numerical values of the pa-
rameters (corresponding to the compound and the species of interest), we obtain
a fully specified and ready to simulate so-called ’simulation object’. The advan-
tage of this orthogonal specification and data management is a large flexibility.
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The same PBPK model can be used for different species and compounds, while
the same species database can be used in studies of different models etc. We now
demonstrate how to user-friendly and efficiently set up a model for three com-
pounds interacting in a way motivated by the Tamiflu example in three steps.
An overview over the necessary modelling steps to be performed is given in Table
1.
Independent pharmacokinetics. To start with, the pharmacokinetics of
the three compounds A, B and C are simulated independently. This is easily
performed by creating a simulation object, which links the full body model,
the species data (rat) and the respective compound data. As a consequence,
MEDICI-PK automatically generates a set of model equations for each com-
pound. In this example we have identical models for the three compounds. The
resulting pharmacokinetic profiles are shown in Fig. 3 (top left panel) for an
intravenous administration of 2 mg/(kg bodyweight) of each compound. Com-
pounds A, B and C show very different pharmacokinetic profiles. This is due
to their distinctive distribution characteristics in the various tissues and due to
their different elimination characteristics. While compound C is eliminated in
an almost constant fashion, compound A and B are eliminated in an exponen-
tial fashion. Plasma levels of compound B are substantially higher than plasma
levels of compound A and C respectively. This is because compound B is mainly
distributed in the plasma, with significantly lower concentrations in the intersti-
tium and cellular space.
Conversion of pro-drug A to B. We next demonstrate how to link the
pharmacokinetics of compound A and B. In physiological terms, we want to
model the conversion of compound A into compound B in the liver. Given the
full body template from the first simulation scenario, this requires only a single
change, namely the adaptation of the metabolism model chosen for compound
B in the liver. We define the so-called multi-compound metabolism model
vmeta = −
V
(1)
maxC
(1)
u
K
(1)
m + C
(1)
u
+
V C2maxC
(2)
u
K
(2)
m + C
(2)
u
and subsequently map B to C(1) and A to C(2) in the simulation object. Assum-
ing no i.v. administration of compound B, the simulation results are shown in
Fig. 3 (top right panel) for intravenous administration of 2 mg/(kg body weight)
of compound A and C.
While the simulation of non-interacting compounds based on the same PBPK
model can be solved by successive simulation of a single compound at a time,
the consideration of (dynamic) interactions requires to establish a joint model
for the interacting compounds. In MEDICI-PK, this is automatically generated
exploiting the described software concept. This will become even more obvious
in the next case.
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Competition for active tubular excretion. Finally, we want to include
the drug-drug interactions between compound B and C. In physiological terms,
compound C will compete with compound B for active excretion. Given the full
body template from the second simulation scenario, this again requires only a
single change. We modify eq. (2) to include the competition by
v
(1)
CLren
= QGFC
(1)
u
+
V
(1)
maxC
(1)
u
K
(1)
m (1 +
C
(2)
u
K
(2)
m
) + C
(1)
u
−Qre−abs.
(1)C(1)
u
v
(2)
CLren
= QGFC
(2)
u
+
V
(2)
maxC
(2)
u
K
(2)
m (1 +
C
(1)
u
K
(1)
m
) + C
(2)
u
−Qre−abs.
(2)C(2)
u
As with the case of Oseltamivir-Probenicid competitive inhibition, uni-directed
inhibition can be achieved by greatly diverging Km values (factor 10
4) for com-
pounds B and C. After mapping B to C(1) and C to C(2) in the simulation object,
the simulation is performed; the results are shown in Fig. 3 (middle and bottom
panels) for intravenous administration of 2 mg/(kg body weight) of compound A
and C. This example nicely illustrates the phenomenon of extended drug expo-
sition of compound B (active metabolite) as a result of a drug-drug interaction.
In our physiological context (Fig. 1), a total of 162 ordinary differential equations
is necessary to simulate the pharmacokinetics of the three compounds, includ-
ing drug-drug interactions; – on the basis of the presented concepts, MEDICI-
PK generates these equations from seven user-defined local physiological models
only!
5 Conclusion & Outlook
Considerable progress has been made in the development of in silico models to
predict and understand the pharmacokinetics of new compounds, in particular
in early drug discovery. As a result, modelling and simulation is possible prior to
any in vivo experiments, solely based on in vitro data. We present the principles
and concepts of a software design that efficiently allows to build up PBPKmodels
in terms of the underlying physiological processes, combining user-friendliness
and flexibility. These principles and concepts are the basis of the software tool
Medici-PK that has been used to illustrate our approach.
We believe that the combination of in vitro experiments and in silico mod-
eling has the potential to drastically increase the insight and knowledge about
relevant physiological and pharmacological processes in drug discovery. In antic-
ipation of modelling not only the distribution of the drug in the body, but also
its effect (disease modelling), one future challenge will be the combination of
pharmacokinetics and effect related metabolic networks or signalling pathways
for a better understanding of the disease dynamics. An example would be the
treatment-induced selective pressure on viral dynamics. The presented concepts,
realized in Medici-PK, are powerful and flexible enough to also support these
future tasks.
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